Information Provided By:
Fly News Breaks for December 18, 2018
ACRS, CNCE
Dec 18, 2018 | 06:33 EDT
Mizuho analyst Difei Yang reiterates a Buy rating on Concert Pharmaceuticals (CNCE) after competitor Aclaris Therapeutics (ACRS) reported data from its topical Janus kinase 1/3 inhibitor for the treatment of alopecia areata. While a number of patients were responders in the eyebrow and alopecia totalis/alopecia universalis Phase 2 trials, improvements on Severity of Alopecia Tool scores were not disclosed and a few patients withdrew from the studies, Yang tells investors in a research note. The analyst sees Concert Pharmaceuticals' CTP-543 as best-in-class and more competitive for the treatment of moderate/severe alopecia areata. Yang keeps a $26 price target on Concert shares.
News For CNCE;ACRS From the Last 2 Days
There are no results for your query CNCE;ACRS